Medical Research News

Nursing

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Debinski W et al. – The first Phase III trial for CED–delivered, molecularly targeted cytotoxin in the treatment of recurrent glioblastoma multiforme has been accomplished and demonstrated objective clinical efficacy. The lessons learned from more than a decade of attempts at exploiting CED for brain cancer treatment weigh critically for its future clinical applications. The main issues center around the type of catheters used, number of catheters and their exact placement; pharmacological formulation of drugs, prescreening patients undergoing treatment and monitoring the distribution of drugs in tumors and the tumor–infiltrated brain. It is expected that optimizing CED will make this technology a permanent addition to clinical management of brain malignancies.

Related Articles

Brain Tumor Survivors Speak Out
Journal of Pediatric Oncology Nursing, 10/26/09    Relevance Score: 70%

Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper
Journal of Neuro-Oncology, 10/26/09    Relevance Score: 70%

Endocrine Late Effects in Survivors of Pediatric Brain Tumors
Journal of Pediatric Oncology Nursing, 10/26/09    Relevance Score: 69%

Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors
Annals of the Indian Academy of Neurology, 10/16/09    Relevance Score: 69%

Brain damage from anticancer treatments in adults
Current Opinion in Oncology, 10/13/09    Relevance Score: 68%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address